132.25
price up icon1.23%   1.61
after-market アフターアワーズ: 132.25
loading
前日終値:
$130.64
開ける:
$129.12
24時間の取引高:
1.32M
Relative Volume:
1.19
時価総額:
$13.27B
収益:
$2.68B
当期純損益:
$428.00M
株価収益率:
31.58
EPS:
4.1873
ネットキャッシュフロー:
$593.10M
1週間 パフォーマンス:
+2.81%
1か月 パフォーマンス:
-1.22%
6か月 パフォーマンス:
-4.26%
1年 パフォーマンス:
+12.54%
1日の値動き範囲:
Value
$129.12
$132.99
1週間の範囲:
Value
$126.59
$132.99
52週間の値動き範囲:
Value
$84.23
$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1111)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
132.25 13.11B 2.68B 428.00M 593.10M 4.1873
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
18.75 58.54B 29.85B 776.90M 4.35B 0.2408
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
131.10 54.78B 9.47B 2.67B 2.28B 6.0218
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.07 47.92B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
33.86 39.33B 17.41B 1.43B 1.00B 1.2182
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
503.90 21.68B 3.13B 1.27B 1.12B 26.39

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
09:37 AM

Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - Yahoo Finance UK

09:37 AM
pulisher
06:22 AM

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Primecap Management Co. CA - MarketBeat

06:22 AM
pulisher
Feb 26, 2026

Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics - Markets Mojo

Feb 26, 2026
pulisher
Feb 26, 2026

9,887 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Fox Run Management L.L.C. - MarketBeat

Feb 26, 2026
pulisher
Feb 25, 2026

Does Strong Q4 Results And INGREZZA Guidance Change The Bull Case For Neurocrine Biosciences (NBIX)? - simplywall.st

Feb 25, 2026
pulisher
Feb 25, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by Wolfe Research - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Wolfe Research initiates Neurocrine stock at Outperform on drug pipeline - Investing.com Australia

Feb 25, 2026
pulisher
Feb 25, 2026

Neurocrine Biosciences stock rating reaffirmed at RBC on takeout potential - Investing.com Australia

Feb 25, 2026
pulisher
Feb 24, 2026

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March - The AI Journal

Feb 24, 2026
pulisher
Feb 24, 2026

Neurocrine plans March fireside chats at TD Cowen and Leerink - Stock Titan

Feb 24, 2026
pulisher
Feb 24, 2026

Wolfe Research initiates Neurocrine stock at Outperform on drug pipeline By Investing.com - Investing.com Canada

Feb 24, 2026
pulisher
Feb 24, 2026

Neurocrine Biosciences stock rating reaffirmed at RBC on takeout potential By Investing.com - Investing.com India

Feb 24, 2026
pulisher
Feb 24, 2026

Investment Review: Is Neurocrine Biosciences Inc a strong growth stockWeekly Profit Summary & Safe Capital Growth Plans - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 24, 2026

Wolfe Research Begins Coverage on Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat

Feb 24, 2026
pulisher
Feb 24, 2026

Wolfe Research Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform Recommendation - Nasdaq

Feb 24, 2026
pulisher
Feb 24, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and a Bullish Chart Pattern - ChartMill

Feb 24, 2026
pulisher
Feb 24, 2026

A Look At Neurocrine Biosciences (NBIX) Valuation After Positive Analyst Views And 2026 Guidance - simplywall.st

Feb 24, 2026
pulisher
Feb 23, 2026

Truist Lowers Neurocrine Biosciences, Inc.’s (NBIX) PT Following 2026 Outlook Update - Insider Monkey

Feb 23, 2026
pulisher
Feb 23, 2026

Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update - Finviz

Feb 23, 2026
pulisher
Feb 23, 2026

Is It Time To Reassess Neurocrine Biosciences (NBIX) After Recent Share Price Weakness - Yahoo Finance

Feb 23, 2026
pulisher
Feb 21, 2026

Vanguard Group Inc. Decreases Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Feb 21, 2026
pulisher
Feb 20, 2026

Neurocrine Biosciences, Inc. $NBIX Position Trimmed by Persistent Asset Partners Ltd - MarketBeat

Feb 20, 2026
pulisher
Feb 20, 2026

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Fiera Capital Corp - MarketBeat

Feb 20, 2026
pulisher
Feb 20, 2026

Aberdeen Group plc Reduces Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Feb 20, 2026
pulisher
Feb 20, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Cut to “Strong Sell” at Zacks Research - Defense World

Feb 20, 2026
pulisher
Feb 19, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat

Feb 19, 2026
pulisher
Feb 19, 2026

Skandinaviska Enskilda Banken AB publ Reduces Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Feb 19, 2026
pulisher
Feb 19, 2026

Neurocrine (NASDAQ:NBIX) Downgrade Shifts Focus Across Nasdaq Index - Kalkine Media

Feb 19, 2026
pulisher
Feb 19, 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Feb 19, 2026
pulisher
Feb 18, 2026

Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza - Yahoo Finance

Feb 18, 2026
pulisher
Feb 18, 2026

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Eagle Health Investments LP - MarketBeat

Feb 18, 2026
pulisher
Feb 18, 2026

New Strong Sell Stocks for February 18th - Yahoo Finance

Feb 18, 2026
pulisher
Feb 18, 2026

JPMorgan Chase & Co. Has $664.02 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Feb 18, 2026
pulisher
Feb 17, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $176.00 at JPMorgan Chase & Co. - MarketBeat

Feb 17, 2026
pulisher
Feb 17, 2026

Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN

Feb 17, 2026
pulisher
Feb 17, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $140.00 by Analysts at Truist Financial - MarketBeat

Feb 17, 2026
pulisher
Feb 17, 2026

Truist cuts Neurocrine Bio stock price target on higher spending By Investing.com - Investing.com Canada

Feb 17, 2026
pulisher
Feb 17, 2026

M&G PLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Feb 17, 2026
pulisher
Feb 17, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation - ChartMill

Feb 17, 2026
pulisher
Feb 16, 2026

Wall Street Zen Downgrades Neurocrine Biosciences (NASDAQ:NBIX) to Buy - MarketBeat

Feb 16, 2026
pulisher
Feb 15, 2026

Volatility Watch: Is Appian Corporations ROIC above industry averageMarket Activity Report & Technical Buy Zone Confirmation - baoquankhu1.vn

Feb 15, 2026
pulisher
Feb 15, 2026

Neurocrine Biosciences (NBIX) Valuation Check After Strong 2025 Results And Late Stage Pipeline Progress - simplywall.st

Feb 15, 2026
pulisher
Feb 15, 2026

Why Neurocrine Biosciences Inc. (NB3) stock is a strong analyst pickQuarterly Growth Report & Safe Entry Zone Identification - mfd.ru

Feb 15, 2026
pulisher
Feb 15, 2026

Technical Reactions to NBIX Trends in Macro Strategies - Stock Traders Daily

Feb 15, 2026
pulisher
Feb 14, 2026

Market Rankings: Why is Neurocrine Biosciences Inc. stock going upWeekly Trend Report & Technical Pattern Based Signals - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

Can Neurocrine Biosciences Inc. maintain its current growth rateStop Loss & AI Powered Buy and Sell Recommendations - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

Neurocrine Biosciences (NBIX) Is Down 12.1% After Issuing 2026 INGREZZA Sales GuidanceWhat's Changed - simplywall.st

Feb 14, 2026
pulisher
Feb 14, 2026

Why Neurocrine Biosciences Inc. stock remains a top recommendationJuly 2025 Fed Impact & Long-Term Safe Investment Plans - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance - Yahoo Finance

Feb 14, 2026
pulisher
Feb 14, 2026

How cyclical is Neurocrine Biosciences Inc.’s revenue streamWeekly Investment Recap & Low Risk Profit Maximizing Plans - mfd.ru

Feb 14, 2026
pulisher
Feb 13, 2026

UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating - marketscreener.com

Feb 13, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$26.40
price up icon 0.80%
drug_manufacturers_specialty_generic RGC
$26.23
price down icon 0.23%
drug_manufacturers_specialty_generic RDY
$14.38
price down icon 1.37%
$14.93
price down icon 2.10%
$503.90
price up icon 0.06%
大文字化:     |  ボリューム (24 時間):